Boulder-based Edgewise Therapeutics raises $50M in Series B round
BOULDER — Edgewise Therapeutics Inc. closed a $50 million Series B fundraising round for its research into musculoskeletal diseases.
According to a press release, Edgewise said the funding will be used to prepare its main drug candidate, a treatment for two forms of muscular dystrophy, for clinical trials. The company is seeking Investigational New Drug status from the U.S. Food and Drug Administration.
The round was led by Danish venture firm Novo Holdings A/S and California-based U.S. Venture Partners LP.
Edgewise, which is affiliated with the University of Colorado Boulder’s BioFrontiers Institute, is developing therapies for muscular disorders. CEO Kevin Koch told BizWest…
THIS ARTICLE IS FOR SUBSCRIBERS ONLY
Continue reading for less than $3 per week!
Get a month of award-winning local business news, trends and insights
Access award-winning content today!
Related Posts
-
Ann Schmiesing, vice chancellor and executive vice provost for Academic Resource Management at the University…
-
TiFin Group , a Boulder-based financial technology umbrella company, has offloaded its ownership stake in…
-
Downtown Boulder’s Business Improvement District is recruiting two at-large board members.
-
Broomfield-based Premier Members Credit Union opened a new branch this week at 1425 S. Airport…
